Inovio's shares boosted on positive H1N1 trials

After a year of trading below $1, shares of Inovio Biomedical soared to $3.18 yesterday. The revival was sparked by the San Diego based company's announcement of positive results from animal studies of the company's H1N1 vaccine, SynCon. The DNA-based vaccine protected 100 percent of the test subjects against the newest strain of H1N1 for which developers are racing to create a vaccine. But the vaccine was designed to protect against a different strain--a result the company says demonstrates its potential as a universal vaccine.

The vaccine will not make it to the market for a few years but that didn't deter investors, who also boosted the shares of Vical and Novavax on the news. "It's not any kind of immediate solution to the potential crisis this fall," CEO Dhillon said in an interview. "But it is a longer-term solution that could have some very big applications."

Inovio hopes to begin testing the vaccine in humans. Capitalizing on the peak in interest, the company announced this morning plans to raise $30 million through a registered direct offering.

- read the release on the RDO
- here's the release on the study results
- more on the vaccine at Forbes

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.